Earnings Call Intelligence Subscribe
Home › Call Sheets › AMGN › Q3'25
Call sheet · Q3'25

Amgen (AMGN)

Q3'25 earnings call · held 2025-11-04 · compared with the Q2'25 call · management-credibility review
9/12
Disclosure score
1 medium, 4 low flags
Financial quality
Bottom line
The sleeper story is Amgen building direct-pay infrastructure while everyone focuses on pipeline readouts. AmgenNow isn't just patient access theater - at $239/month for Repatha, they're creating a post-rebate commercial model that could reshape how they price and distribute. The obvious headline is 14% volume growth and raised guidance, but the binding constraint is their R&D appetite - 31% spending growth shows they're prioritizing pipeline over margins as competitive threats loom. Bradner's quote on MariTide Part 2 being 'more descriptive' with limited power for weight loss insights should temper Q4 expectations. My view changes if AmgenNow scales beyond Repatha or if VESALIUS-CV drives meaningful primary prevention uptake.

The 30-second version

  • SLEEPER STORY: They're quietly becoming a direct-pay pharmacy with AmgenNow
  • Volume growth (14%) masking a margin compression story as R&D jumps 31%
  • MariTide Part 2 data deliberately underpowered for weight loss comparisons

What changed this quarter

MetricQ2'25Q3'25Change
Total Revenue$9.2B (+9% YoY)$9.6B (+12% YoY)+300 bps acceleration
Volume Growth13% YoY14% YoY+100 bps improvement
Non-GAAP Operating MarginNot specified Q247%Compressed from historical levels
Non-GAAP R&D Expense+18% YoY+31% YoY+1300 bps acceleration
Free Cash Flow$1.9B Q2$4.2B Q3+121% sequential jump
Repatha Sales$696M (+31% YoY)$794M (+40% YoY)+900 bps acceleration
EVENITY Sales$518M (+32% YoY)$541M (+36% YoY)+400 bps acceleration
IMDELLTRA Sales$134M Q2$178M Q3+33% sequential growth
Rare Disease Portfolio$1.4B (+19% YoY)$1.4B (+13% YoY)-600 bps deceleration
Biosimilar Revenue$661M (+40% YoY)$775M (+52% YoY)+1200 bps acceleration

Accountability tracked

7 new promises made4 narrative shifts flagged6 prior promises scored
Inside the full report
The complete write-up covers the full promise ledger with kept/missed calls, disclosure-quality scoring, the metrics-vanished check, verification items, and the questions to ask next quarter.
Read the full AMGN Q3'25 report Subscribe
About Research ↗Call SheetsCredibility IndexMissed PromisesScreens13F BooksData & InstitutionalPrivacyTermsSubscribe
This is a free preview. The full write-up and promise ledger are published to subscribers on Substack.
Scores, kept-promise rates, and flags on this site reflect the author's opinion, applying a stated methodology to statements management made on public earnings calls. Informational and educational purposes only - not investment advice, a recommendation, or an offer to buy or sell any security. Sources believed reliable but not guaranteed; the author may hold positions in the securities discussed.

Follow what management promises next

Get free previews of our earnings-call research: the key changes, management scores, and questions worth investigating. Subscribe for full call sheets and deeper analysis.

Subscriptions are managed by Substack. If the form does not load, subscribe directly. Or follow the RSS feed.